Cite
HARVARD Citation
Tolaney, S. et al. (n.d.). Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. European journal of cancer. pp. S16-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Tolaney, S. et al. (n.d.). Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. European journal of cancer. pp. S16-. [Online].